Thursday, January 17, 2013 12:10:35 PM
Make a comment
By Ed Silverman // January 17th, 2013 // 11:16 am
Earlier this month, NPS Pharmaceuticals announced that the price for its Gattex treatment for short-bowel syndrome would cost $295,000 a year, roughly three times what Wall Street had expected. This marked the fourth time in the past year that an orphan drug was approved and the price per patient was set at more than $200,000 annually. The move highlighted a growing debate about the calculations used for developing new medications designed for small patient populations and the ability of the healthcare system to afford these treatments and accommodate patients. We spoke with Randy Vogenberg, a principal at the Bentelligence consulting firm, which specializes in benefits consulting and strategic decision making, about the implications for drug makers and payers…
Pharmalot: Why are we seeing this kind of pricing?
Vogenberg: I think part of the reason is that we’re dealing with smaller patient populations than in the past and that’s the typical situation. There are hundreds instead of however many tens of thousands of patients and then we’re spreading cost among a smaller group. So unit costs rise dramatically. And there’s a Catch 22 around pricing – which is a little unique around specialty (drugs). You have a smaller number (of patients) and charging a higher price, so there’s a higher percentage of patients who can’t afford it. This means there’s greater need for unrestricted grants and patient assistant programs. So as a company, you end up paying more for your own product than in the older, traditional marketplace.
more...
http://www.biotechinvestorsnetwork.com/#!featured-article/c17ob
Recent VRTX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:13:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/04/2024 08:12:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 08:47:28 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/30/2024 08:23:37 PM
- Vertex to Participate in Upcoming September Investor Conferences • Business Wire • 08/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:04:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 08:08:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/08/2024 08:06:24 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/08/2024 03:47:17 PM
- Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England • Business Wire • 08/07/2024 11:12:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/07/2024 01:52:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 08:10:07 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/02/2024 08:03:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:17:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:05:43 PM
- Vertex Reports Second Quarter 2024 Financial Results • Business Wire • 08/01/2024 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/01/2024 07:34:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/30/2024 07:25:57 PM
- Vertex Announces FDA Acceptance of New Drug Application for Suzetrigine for the Treatment of Moderate-to-Severe Acute Pain • Business Wire • 07/30/2024 05:10:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2024 08:06:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/24/2024 08:05:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/24/2024 04:27:07 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/22/2024 05:16:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/17/2024 08:13:27 PM
- Santé Canada autorise la commercialisation de TRIKAFTA(MD) (éléxacaftor/tézacaftor/ivacaftor et ivacaftor) chez les personnes atteintes de fibrose kystique âgées de 2 ans et plus présentant certaines mutations rares • PR Newswire (Canada) • 07/15/2024 01:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM